This message contains images. If you don't see images, click here to view.
Advertise in this news brief.


Text version   RSS   Subscribe   Unsubscribe   Archive   Media Kit December 7, 2016    SLAS2017    Moving? New job? Let SLAS know.      







Eight Exciting Entrepreneurs Earn Invitations to SLAS2017 Innovation AveNEW
SLAS    Share    Share on FacebookTwitterShare on LinkedinE-mail article
These promising new start-up companies kick off 2017 by bringing their novel technologies to the SLAS2017 Exhibition. Selected by a panel of judges from a pool of impressive applicants, these SLAS Innovation AveNEW entrepreneurs earn complimentary exhibit space, travel, hotel and conference registration; all to put them and their scientific innovations face-to-face with the world-class professionals at SLAS2017 in Washington, DC, Jan. Feb. 4-8. Congratulations to: More


SLAS ELN Reports: Uniting Phenotypic and Target-Based Drug Discovery
SLAS    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Many people see target-based drug discovery and the phenotypic approach to drug discovery as antagonistic but Fabien Vincent, associate research fellow in the Department of Hit Discovery and Lead Profiling at Pfizer, sees them as complementary. This is the message he and fellow presenter David Swinney hope to convey during the SLAS2017 session "Uniting Phenotypic and Target-based Drug Discovery," part of the Drug Target Strategies Track.

"It's not us vs. them," Vincent says. "We are likely going to be more successful when we intelligently combine the two."

Sponsored Content

SLAS Journal News
SLAS    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Two new scientific reports are now available ahead-of-print for FREE to all readers at JBS Online. An original research paper by Ioannis K. Moutsatsos et al. and a technical note by Andreas Stengl et al. reflect the quality and diversity of peer-reviewed science published by the SLAS journals.

Jenkins-CI, an Open-Source Continuous Integration System, as a Scientific Data and Image-Processing Platform

A Simple and Sensitive High-Content Assay for the Characterization of Antiproliferative Therapeutic Antibodies

Coming soon: Readers will begin seeing the SLAS journals identified by their new names (SLAS Discovery and SLAS Technology) within the next week. While the names are changing, the journals' trusted commitment to innovation is not changing. Their editorial rigor, integrity, aims and scope remain solidly in place.

Accelerate your NGS Success

Fast, accurate sequencing begins with automated NGS Sample Prep from Agilent.

SLAS Europe Translating Research Ideas Into Future Therapeutics Conference a Success
SLAS     Share    Share on FacebookTwitterShare on LinkedinE-mail article
A highly engaged group of academic scientists, innovative start-ups and funding organizations from across Europe gathered to discuss how to streamline project selection to deal making at the Nov. 29-30, 2016, conference in Leuven, Belgium.

"Participants had a wonderful opportunity to talk at length with each other about their projects, learn from one another’s experience, build new alliances and create new development partnerships," notes Caroline Gutierrez, SLAS Europe director.


Yes! You Can Publish Open Access with SLAS Journals
SLAS    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Authors who wish to make their work freely available immediately upon publication in SLAS journals may do so for a fee of $3,000. Typically, access to scientific content is limited to SLAS members and subscribers and available on a pay-per-view basis until one year after final (print) publication. But this is not mandatory.

SAGE Choice (gold open access) ensures authors can comply with funding mandates and helps authors attract more readership more quickly.

SLAS2017 Short Course Spotlight: Next Generation Sequencing Technology Fundamentals and Applications
SLAS    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Next generation sequencing (NGS) has revolutionized genomics. It has created a novel set of applications and industries in such diverse fields as agriculture, the environment, human origins, infectious diseases and human health. Besides introducing basic concepts, this course provides a glimpse of future through groundbreaking applications.

Course instructors are Dawei Lin of the Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, and Abizar Lakdawalla of Proxeom. Next Generation Sequencing Technology Fundamentals and Applications is one of 21 Short Courses to be held at SLAS2017.

Sponsored Content


Scientists Use CRISPR for First Time to Correct Clotting in Newborn and Adult Mice
Lab Manager    Share    Share on FacebookTwitterShare on LinkedinE-mail article
CRISPR/Cas9, a powerful genome editing tool, is showing promise for efficient correction of disease-causing mutations. For the first time, researchers from the Perelman School of Medicine at the University of Pennsylvania have developed a dual gene therapy approach to deliver key components of a CRISPR/Cas9-mediated gene targeting system to mice to treat hemophilia B. This disorder is also called factor IX deficiency and is caused by a missing or defective clotting protein. More

Turning Blood Cells Into Light-Controlled Drug Carriers
Chemical & Engineering News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Red blood cells, the most numerous type of cell in the body, can act as light-activated drug delivery vehicles, according to a new study. The technique traps drugs in the cells, where they could circulate for the cells' four-month lifetimes. Red or infrared light shone on a patient's skin or through an inserted fiber optic could release the trapped drugs when and where they are needed. In the technique, David S. Lawrence of the University of North Carolina, Chapel Hill, and coworkers first covalently attach a drug and a fluorescent molecule to cobalamin, the core structure of vitamin B-12. More


Survey of Approved Drugs Intended to Shed Light on Potential New Therapies
Genetic Engineering & Biotechnology News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Researchers have created a map of all 1,578 licensed drugs and their mechanisms of action as a means of identifying "uncharted waters" in the search for future treatments. Their analysis of drugs licensed through the U.S. FDA reveals that 667 separate proteins in the human body have had drugs developed against them — just an estimated 3.5% of the 20,000 human proteins. And as many as 70% of all targeted drugs created so far work by acting on just four families of proteins, thus leaving vast swathes of human biology untouched by drug-discovery programs. More

USPTO to Hear Arguments on CRISPR Patents
The Scientist    Share    Share on FacebookTwitterShare on LinkedinE-mail article
CRISPR, the gene-editing technology that has taken the scientific community by storm, will have its day in court as three judges at the United States Patent and Trademark Office hear oral arguments to decide who owns the valuable intellectual property over its use. "The Broad Institute [of MIT and Harvard] is requesting priority based on its patent application filed on December 12, 2012," Life Sciences Intellectual Property Review reported. More

NG Sequencing: Large DNA Fragments

Digilab’s NextGen Shear DNA Shearing system offers the simplest,most reproducible, & most controllable method available on the market for generating random, especially large DNA fragments. It is the new generation of DNA shearing devices providing additional automation steps over the regular model. Why settle for less with your research investment?
KMC Systems Engineering & Manufacturing
KMC Systems provides contract engineering and manufacturing services to leading and emerging OEMs. As a trusted outsourcing partner for 35 years, KMC Systems develops, designs and manufactures cutting-edge, full-system instrumentation for the medical and life science markets. Visit us online and download our brochure to learn more about KMC Systems.
Specialized Lab-on-a-Chip solutions
Micronit creates added value for our customers by offering a unique combination of:
1. Microfluidics expertise from design through prototyping to manufacturing.
2. Materials, from glass to polymers, silicon or hybrid combinations.
3. Customer application know-how, which together enable our customers to develop winning products, both now and in the future.

Congress Poised to Back NSF's Approach to Research
Science Magazine    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Congress has reached a truce — and possibly a lasting settlement — in the fiercely partisan three-year war between Republican leaders in the House of Representatives and the scientific community over how the National Science Foundation should operate. The terms of the agreement, between House and Senate negotiators, may seem like minor changes. But the compromise, which the Senate could adopt as early as this week, resolves differences over how NSF should conduct peer review and manage research in ways that the agency thinks it can live with. More

New Method Improves Stability, Extends Shelf Life of Protein Drugs    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Gaining access to important biopharmaceuticals needed to treat illnesses and autoimmune diseases is one of the biggest obstacles developing countries face. Costs can be astronomical where these medications are needed most, and when doctors are able to acquire those medications they face another challenge — time. Drugs are perishable and some require refrigeration, which can be difficult to provide in the world's poorest regions. Now, a new study appearing in the Proceedings of the National Academy of Sciences reveals a new way to improve the stability of common protein drugs and extend shelf life. More

Researchers Uncover More Genetic Links to Brain Cancer Cell Growth
Bioscience Technology    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Two recently discovered genetic differences between brain cancer cells and normal tissue cells — an altered gene and a snippet of noncoding genetic material — could offer clues to tumor behavior and potential new targets for therapy, Johns Hopkins scientists report. In a report on one of the two findings, published online in Acta Neuropathologica, the investigators identified alterations in a protein known as ATRX in human brain tumors that arise as part of a genetically inherited condition known as neurofibromatosis type 1. More

Names and Symbols of 4 Newly Discovered Elements Announced
Science Daily    Share    Share on FacebookTwitterShare on LinkedinE-mail article
On Nov. 28, the International Union of Pure and Applied Chemistry (IUPAC) approved the name and symbols for four elements: nihonium (Nh), moscovium (Mc), tennessine (Ts) and oganesson (Og), respectively for element 113, 115, 117 and 118. Following a 5-month period of public review, the names earlier proposed by the discoverers have been approved by the IUPAC Bureau. More


Advance Registration: Dec. 19, 2016
Discounted Hotel Reservations: Jan. 5, 2017
Poster Submissions: Jan. 23, 2017


Senior Scientist, Discovery Oncology
US – CA – South San Francisco

Staff Scientist
National Institute on Deafness and Other Communication Disorders
US – MD – Bethesda

Assistant/Associate Professor in Biological Engineering
University of Guelph
CN – ON – Guelph

Search Jobs at SLAS Career Connections


SLAS Point-to-Point
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Dennis Hall, Executive Editor, 469.420.2656   
Contribute news

This edition of SLAS Point-to-Point was sent to ##Email##. To unsubscribe from receiving SLAS Point-to-Point, click here. To unsubscribe from all SLAS e-mail communications, please click here. Did someone forward this edition to you? Subscribe here — it's free!

SLAS Terms of Use Policy
Recent issues

Nov. 30, 2016
Nov. 23, 2016
Nov. 16, 2016
Nov. 9, 2016

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063